Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced‐dose ibrutinib: results from a multi‐centre study.

The article presents a study of chronic lymphocytic leukaemia patients treated with ibrutinib below the U.S. Food and Drug Administration-recommended starting dose to compare efficacy between the various dosing schedules. Topics discussed include the lack of significant differences in baseline characteristics between the standard-dose and reduced dose cohorts and reasons for ibrutinib dose reduction including gastrointestinal toxicity, bleeding and pharmacokinetic considerations.